ClinicalTrials.gg
RecruitingNCT07030348Updated Nov 18, 2026

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

An observational study in Pancreatic Cancers and Pancreatic Diseases, sponsored by Do Hyun Park. Recruiting at 3 sites in 2 countries. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Do Hyun Park · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
263
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
91st of 230
263 · median 137
Started
2024
with 67 others
Observational
231 of 1,850
70 open now
Primary completion
2027-05
later than 200 of 468 live
Registered
1,734th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 91st largest by planned enrollment of the 230 observational ones that give a count, is one of 68 that started in 2024, is one of 231 observational ones, reaches primary completion later than 200 of the 468 other live ones, and was the 1,734th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable.

Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.

Read the detailed description

Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, which is a very poor prognosis, and only 10-15% of all pancreatic cancer patients are operable or borderline operable.

Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, the biomarkers of humoral fluids associated with the early diagnosis of pancreatic cancer are not well understood.

Duodenal pancreatic fluids can be easily obtained through an endoscopy and contain a large amount of pancreatic fluid secreted by the pancreas, which is known to be a candidate of biomarkers for early diagnosis of pancreatic cancer.

However, there have been few studies using duodenal fluids in Korea. This study aims to prospectively analyze biomarkers for early diagnosis of pancreatic cancer using duodenal fluids obtained by endoscopy in pancreatic and non-pancreatic cancer groups.

03

Conditions studied

  • Pancreatic Cancers
  • Pancreatic Diseases
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who require a gastro-duodenal endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography (ERCP) for medical purposes will be enrolled in this study. The pancreatic cancer group and the control non-pancreatic cancer group will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Among the patients requiring gastro-duodenal endoscopy, endoscopic ultrasound, or ERCP for medical purposes, the pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.

  1. Be at least 19 years old.
  2. Have completed the for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
  3. A with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC).
  4. Suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.

The non-pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.

  1. Be at least 19 years old.
  2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
  3. Patients with pancreatic cystic tumors or patients with acute or chronic pancreatitis.
  4. No evidence of a pancreatic disease.

Exclusion criteria

Exclusion Criteria:

The exclusion criteria for the pancreatic cancer and the non-pancreatic cancer groups will be:

  1. Innate or post-surgical anatomy that precludes direct sampling of duodenal fluid.
  2. Hemodynamically unstable and unable to have an endoscopy performed.
  3. A large amount of ascites fluid that is not controlled and unable to have an endoscopy performed.
  4. A coagulation disorder that cannot be corrected and unable to have an endoscopy performed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
263 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pancreatic Cancer Group (DP)

    Participants with a biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC), or with suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.

  • Non-Pancreatic Cancer Group (DC)

    Participants with pancreatic cystic tumors or with acute or chronic pancreatitis, or with no evidence of a pancreatic disease

06

What researchers measure

Primary outcomes

  1. Identification of Biomarkers for Early Pancreatic Cancer Detection

    Area Under the Receiver Operating Characteristic Curve (AUC) and 95% Confidence Interval (CI) of candidate biomarkers in the training cohort. If the AUC falls within ±5% of the target value (0.94), the optimal cutoff value for pancreatic cancer differentiation will be reported using Youden's Index.

    Time frame: Up to 1 year from baseline

Secondary outcomes

  1. External Validation Using U.S. Samples

    Area under the ROC curve (AUC) of candidate biomarkers in the U.S. validation cohort using cut-off values derived from the Korean training cohort

    Time frame: Up to 2 year from baseline

Other outcomes

  1. Optimizing Sample Collection Volume

    Correlation between duodenal fluid sample volume (mL) and biomarker detection sensitivity (AUC or concentration)

    Time frame: Up to 6 month from baseline

  2. Assessing Racial Differences in Biomarker Expression

    Mean biomarker expression levels in Korean vs. U.S. cohorts as measured in duodenal fluid samples

    Time frame: Up to 2 year from baseline

  3. Evaluating the Impact of Secretin Administration

    Comparison of biomarker concentrations in duodenal fluid with vs. without secretin stimulation

    Time frame: Up to 1 year from baseline

  4. Longitudinal Analysis of non-pancreatic cancer group Samples (Asan Medical Center Only)

    Change in biomarker levels between first and second duodenal fluid samples in non-pancreatic cancer participants

    Time frame: Up to 2 year from baseline

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for May 2027, 40 months after the start.

Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 40 months is below that.

Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2026 → May 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 22, 2025
StartActual
Jan 2, 2024
Primary completionEst.
May 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→May 31, 2027
Nov 18, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Dec 31, 2026→May 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07030348
Lead sponsor
Do Hyun Park
Responsible party
Do Hyun Park (Professor, Asan Medical Center) — Sponsor-investigator
First posted
Jun 22, 2025
Start date
Jan 2, 2024
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

HyeJin Song, CRC
Contact
asangicrc@gmail.com
+82-2-2045-3825

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion